Alma Bio Therapeutics
  • Home
  • About Us
    • About Us
    • The People
  • Our Approach
    • Autoimmune Diseases
    • Our Therapeutic Approach
  • Pipeline
  • News
  • Contact Us

Blog

New PCT: Nucleic acid therapy for differential modulation of host microflora

  • Agnes
  • April 26, 2022
  • News

March 2022 – WO 2022/070052 A1, a new PCT covering the effect of our IBD-asset on gut dysbiosis and impaired barrier function, was published online.

You Might Also Like

Drug Mechanism of Action demonstrated: Mucosal healing without immune suppression

April 26, 2022

4th Antigen Specific Immune Tolerance event

April 13, 2021

ECCO 2022

April 26, 2022

Recent Posts

  • Drug Mechanism of Action demonstrated: Mucosal healing without immune suppression
  • New PCT: Nucleic acid therapy for differential modulation of host microflora
  • ECCO 2022
  • CCFI /Région Auvergne Rhône-Alpes
  • 4th Antigen Specific Immune Tolerance event

Questions? Contact Us!

Site Navigation

  • Home
  • About Us
  • Our Approach
  • Pipeline
  • News
  • Legal Notice

Contact Info

  • ALMA BIO THERAPEUTICS
  • HQ Lyon Vaise Business Center
    3, place Giovanni Da Verrazzano
    Lyon 69009 France
  • +33 4 37 66 47 49
  • message@alma-bio.com
© All Right Reserved to Alma Bio Therapeutics 2018